Arrowhead Pharmaceuticals, Inc.

347 articles with Arrowhead Pharmaceuticals, Inc.

• Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics - October 18, 2019

  10/2/2019

  Arrowhead Pharmaceuticals Inc. announced that it will host a Research & Development Day to discuss its emerging pipeline of RNAi therapeutics that leverage its proprietary Targeted RNAi Molecule platform from 8:30 a.m. to 11:30 a.m. EDT on October 18, 2019, in New York City.

• Arrowhead Pharmaceuticals to Participate in Upcoming October 2019 Conferences

  9/30/2019

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

• Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) - Sept. 20, 2019

  9/20/2019

  Arrowhead Pharmaceuticals Inc. announced that as an inducement to entering into employment with the Company, on September 13, 2019, the Compensation Committee of the Board of Directors approved "inducement" grants to 17 new employees under Rule 5635 of the NASDAQ Marketplace Rules.

• Arrowhead Pharmaceuticals to Participate in Upcoming September 2019 Conferences

  8/30/2019

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events

• Arrowhead Collaborator Janssen Begins REEF-1 Phase 2b Combination Study in Patients with Chronic Hepatitis B Infection

  8/28/2019

  Arrowhead earns $25 million milestone payment in connection with trial initiation

• Arrowhead Pharmaceuticals Doses First Patient in SEQUOIA Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

  8/8/2019

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in SEQUOIA (AROAAT2001), a potentially pivotal Phase 2/3 clinical study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD).

• Arrowhead Pharmaceuticals Reports Fiscal 2019 Third Quarter Results

  8/5/2019

  Conference Call and Webcast Today at 4:30 p.m. EDT

• Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Third Quarter Results

  7/24/2019

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 5, 2019, at 4:30 p.m. EDT to discuss its financial results for the fiscal 2019 third quarter ended June 30, 2019.

• Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-ANG3

  7/16/2019

  Arrowhead Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has granted orphan drug designation to ARO-ANG3 for the treatment of homozygous familial hypercholesterolemia.

• Arrowhead Pharmaceuticals to Participate in Roth RNA Revolution Conference

  7/8/2019

  Arrowhead’s vice president of investor relations will participate in panel discussions at the Roth RNA Revolution Conference on July 17, 2019.

• Arrowhead Pharmaceuticals Receives Fast Track Designation for ARO-AAT for Treatment of Alpha-1 Liver Disease

  6/27/2019

  Arrowhead Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation to ARO-AAT, the company’s second generation subcutaneously administered RNA interference therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.

• Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) - June 21, 2019

  6/21/2019

  Arrowhead Pharmaceuticals Inc. announced that as an inducement to entering into employment with the Company, on June 14, 2019, the Compensation Committee of the Board of Directors approved "inducement" grants to 11 new employees under Rule 5635 of the NASDAQ Marketplace Rules.

• Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-APOC3

  6/21/2019

  Arrowhead Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted orphan drug designation to ARO-APOC3 for the treatment of familial chylomicronemia syndrome.

• Arrowhead Pharmaceuticals to Present at Upcoming June 2019 Conferences

  5/31/2019

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

• Arrowhead Pharmaceuticals Reports Fiscal 2019 Second Quarter Results

  5/8/2019

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2019 second quarter ended March 31, 2019.

• Arrowhead Pharmaceuticals to Present at Upcoming May 2019 Conferences

  5/2/2019

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

• Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen

  4/24/2019

  Arrowhead Pharmaceuticals Inc. announced that it has begun dosing in a new triple combination cohort (cohort 12) that includes JNJ-3989 (formerly ARO-HBV) and additional undisclosed agents selected by Janssen Pharmaceuticals, Inc. in its ongoing Phase 1/2 study (AROHBV1001) in patients with chronic hepatitis B virus (HBV).

• Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Second Quarter Results

  4/24/2019

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 8, 2019, at 4:30 p.m. EDT to discuss its financial results for the fiscal 2019 second quarter ended March 31, 2019.

• 

  Inside Look: Janssen’s HBV Asset Licensed From Arrowhead Could Become Treatment Franchise Corners...

  4/17/2019

  Janssen Pharmaceuticals presented data that showed its RNAi therapeutic candidate exhibited robust effects on the liver disease that takes the lives of more than 900,000 people annually.

• Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

  4/15/2019

  Arrowhead Pharmaceuticals Inc. announced that it has received clearance from the U.S. Food and Drug Administration to proceed with an adaptive Phase 2/3 trial with the potential to serve as a pivotal registrational study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.